You are here

  • Home
  • Archive
  • Volume 11, Issue 8
  • Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Carpenter EL, Van Decar S, Adams AM, et al
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Journal for ImmunoTherapy of Cancer 2023;11:e006665. doi: 10.1136/jitc-2023-006665